Disease-modifying osteoarthritis drugs:<i>in vitro</i>and<i>in vivo</i>data on the development of DMOADs under investigation

Davies, Peter; Graham, Simon Matthew; Macfarlane, Robert J.; Leonidou, Andreas; Mantalaris, Athanasios; Tsiridis, Eleftherios

doi:10.1517/13543784.2013.770837

Cited by 32 publications

(25 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Avocado-soybean has been shown to increase aggrecan synthesis, and to reduce catabolic and pro-inflammatory mediator production by human osteoarthritic chondrocytes . Studies of the effects of avocado-soybean on osteoarthritis reported conflicting results with respect to symptom modification (Davies et al, 2013).…”

Section: Translational Value Of the Animal Studiesmentioning

confidence: 99%

Involvement of the endocannabinoid system in osteoarthritis pain

Porta

Bura

Negrete

et al. 2014

Eur J of Neuroscience

View full text Add to dashboard Cite

Osteoarthritis is a degenerative joint disease associated with articular cartilage degradation. The major clinical outcome of osteoarthritis is a complex pain state that includes both nociceptive and neuropathic mechanisms. Currently, the therapeutic approaches for osteoarthritis are limited as no drugs are available to control the disease progression and the analgesic treatment has restricted efficacy. Increasing evidence from preclinical studies supports the interest of the endocannabinoid system as an emerging therapeutic target for osteoarthritis pain. Indeed, pharmacological studies have shown the anti-nociceptive effects of cannabinoids in different rodent models of osteoarthritis, and compelling evidence suggests an active participation of the endocannabinoid system in the pathophysiology of this disease. The ubiquitous distribution of cannabinoid receptors, together with the physiological role of the endocannabinoid system in the regulation of pain, inflammation and even joint function further support the therapeutic interest of cannabinoids for osteoarthritis. However, limited clinical evidence has been provided to support this therapeutic use of cannabinoids, despite the promising preclinical data. This review summarizes the promising results that have been recently obtained in support of the therapeutic value of cannabinoids for osteoarthritis management.

show abstract

Section: Translational Value Of the Animal Studiesmentioning

confidence: 99%

Involvement of the endocannabinoid system in osteoarthritis pain

Porta

Bura

Negrete

et al. 2014

Eur J of Neuroscience

View full text Add to dashboard Cite

show abstract

“…Although several concerns regarding their efficacy profiles have been raised (28), it was reported that SYSADOAs may play a role as disease modifying drugs in OA (DMOADs) (41), Their efficacy profile for symptom relief in knee OA was recently reported to be good when compared to placebo in a network metaanalysis (42), while a recent randomized controlled trial (RCT) demonstrated the non-inferiority of glucosamine associated to condroitin sulphate versus celecoxib (43). The failure of SYSADOAs and other agents to show being specific treatments for OA that modify both symptoms and disease prosecution could be also ascribed to the fact that different phenotypes of OA may respond in a variable manner to different therapies.…”

Section: The Uncertainty Of Analgesic Treatment In Oamentioning

confidence: 99%

An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease

Roman‐Blas

Bizzi

Largo

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Despite the renewed interest in the search of new compounds for treatment of OA, results have been limited. Novel systemic and IA administered agents are in active development. IA drug administration is particularly an attractive approach because can diminish some of the severe side effects associated with systemic drugs. Indeed, one of the most promising fields for pharmacology innovation in OA is joint injected therapy, as suggested by preliminary data from recent studies using IA sprifermin (rhFGF-18), mesenchymal stem cells or TGF-B1 transduced allogenic chondrocytes. Last, the effort to develop new drugs must be accompanied by the interest for establishing well-defined phenotypes, and only then, a more tailored therapy should be practiced in OA.

show abstract

“…While no effective therapy to treat OA is yet available, recent research shows promising disease-modifying properties of several drug candidates [4][5][6]. For instance, fibroblast growth factors FGF-2 and FGF-18, transforming growth factor TGF-β, and insulin-like growth factor IGF-1 promote cartilage homeostasis promote cartilage homeostasis [7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Delivery of Agents Into Articular Cartilage With Electric Spark-Induced Sound Waves

et al. 2018

View full text Add to dashboard Cite

Localized delivery of drugs into articular cartilage (AC) may facilitate the development of novel therapies to treat osteoarthritis (OA). We investigated the potential of spark-gap-generated sound to deliver a drug surrogate, i.e., methylene blue (MB), into AC. In vitro experiments exposed bovine AC samples to either simultaneous sonication and immersion in MB (Treatment 1; n = 10), immersion in MB after sonication (Control 1; n = 10), solely immersion in MB (Control 2; n = 10), or neither sonication nor immersion in MB (Control 3; n = 10). The sonication protocol consisted of 1,000 spark-gap-generated pulses. Delivery of MB into AC was estimated from optical absorbance in transmission light microscopy. Optical absorbance was significantly greater in the treatment group up to 900 µm depth from AC surface as compared to all controls. Field emission scanning electron microscopy (FESEM), histological analysis, and digital densitometry (DD) of sonicated (n = 6) and non-sonicated (n = 6) samples showed no evidence of sonication-induced changes in proteoglycan content or collagen structure. Consequently, spark-gap-generated sound may offer a solution for localized drug delivery into AC in a non-destructive fashion. Further research on this method may contribute to OA drug therapies.

show abstract

Disease-modifying osteoarthritis drugs:in vitroandin vivodata on the development of DMOADs under investigation

Cited by 32 publications

References 74 publications

Involvement of the endocannabinoid system in osteoarthritis pain

Involvement of the endocannabinoid system in osteoarthritis pain

An update on the up and coming therapies to treat osteoarthritis, a multifaceted disease

Delivery of Agents Into Articular Cartilage With Electric Spark-Induced Sound Waves

Contact Info

Product

Resources

About